Xencor, Inc. (NASDAQ:XNCR), reported top-line interim results from a Phase 1a study for XmAb®7195. The data show rapid reduction of circulating free IgE levels to below the limit of detection in 90% of XmAb7195 treated subjects that had detectable freeRead More

BTIG Research initiated coverage on shares of Histogenics Corp (NASDAQ:HSGX) in a research report released on Friday morning, TheFlyOnTheWall.com reports. The firm issued a buy rating and a $13.00 price objective on the stock. On Wednesday shares of Histogenics CorporationRead More

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer and Mr. Stephen Tulipano, Chief Financial Officer of Aldeyra, will participate in the Canaccord Genuity Rare Disease, BioPharma One-on-One Day, being held on Tuesday,Read More

Array BioPharma Inc. (NASDAQ:ARRY) will Report Financial Results For The Second Quarter Of Fiscal 2015 On February 3, 2015. On Tuesday shares of Array BioPharma, Inc. (NASDAQ:ARRY) closed at $7.64. Company’s sales growth for last 5 years was 11.00% andRead More

Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) announced that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. Food and Drug Administration (FDA) for the company’s Iomab-B drug candidate currently undergoing final preparations to start the pivotalRead More

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) and Intrexon Corp. announced on 14 January that they have entered into a license agreement with The University of Texas M.D. Anderson Cancer Center to develop cancer treatments. On Tuesday shares of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)Read More

Array BioPharma Inc. (NASDAQ:ARRY) announced on 23 January that it has reached a definitive agreement to acquire the worldwide rights to encorafenib from Novartis Pharma.On Monday shares of Array BioPharma, Inc. (NASDAQ:ARRY) closed at $7.80. Company’s sales growth for lastRead More

Array BioPharma Inc. (NASDAQ:ARRY) will report financial results for the second quarter of fiscal 2015 and hold a conference call to discuss those results on Tuesday February 3 2015. On Monday shares of Array BioPharma, Inc. (NASDAQ:ARRY) closed at $7.80.Read More

Array Biopharma (NASDAQ:ARRY) was the target of a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 18,577,143 shares, a decrease of 12.3% from the December 15th total of 21,193,329Read More

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 1 clinical study of ADXS-HER2 (ADXS31-164) for the treatmentRead More